MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade

MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) gapped up prior to trading on Thursday after Rothschild and Co Redburn upgraded the stock from a neutral rating to a buy rating. The stock had previously closed at $16.23, but opened at $17.20. Rothschild and Co Redburn now has a $40.00 price target on the stock, up